Comparison
BPC-157 vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Healing
Metabolic
CAS no.
137525-51-0
2179963-22-7
Molecular weight
1419.5 g/mol
4727 g/mol
Half-life
4 h
168 h
Sequence
GEPPPGKPADDAGLVmodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Animal model
Human RCT
Studies
4
2
of which in humans
0
2
Effects recorded
4
3
Open conflicts
2
0
Documented adverse events
2
2